Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With Bevasizumab
Status:
Unknown status
Trial end date:
2019-12-30
Target enrollment:
Participant gender:
Summary
Due to the radiosensitivity of the lung, radiation-induced and chemotherapy-induced
pneumonitis and pulmonary fibrosis are frequent happened following cancer therapy. It not
only compromise cancer treatment, but also influence patient's life qualities and even death.
there are no specific treatment modalities for this treatment-induced complication.
Bevasizumab (Avastin), a VEGF inhibitor, can attenuate serum high expression VEGF and
pulmonary permeability, maybe effective in the control acute pulmonary fibrosis. Patients
will be randomized to receive Bevasizumab (7mg/kg iv) on day one and 21, followed by
Dexamethasone （10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20) or Dexamethasone alone.
The thoracic CT, plasma TNF-a, IL-6, VEGF and C-reactive protein are accessed on before
treatment, 24 hours after Bevasizumab, 7 days, 4 and 8 weeks. the target sample size is 30
cases.